Karen A. Tourian, MD | Psychiatrist.com

Article

Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial

August 27, 2015

A frequent question raised by clinicians is "How are the patients who are continued on antidepressant treatment on a long-term basis actually doing?" Boyer and colleagues explore this question...

Patrice Boyer, Cécile Vialet, Eunhee Hwang, et al

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Anita H. Clayton, Karen A. Tourian, Kristen Focht, et al

Original Research

Efficacy and Safety of Desvenlafaxine 50 mg/d for Prevention of Relapse in Major Depressive Disorder: A Randomized Controlled Trial

February 15, 2013

Joshua Z. Rosenthal, Patrice Boyer, Cécile Vialet, et al

Letter to the Editor

Correction for "Desvenlafaxine and Weight Change in Major Depressive Disorder"

November 7, 2011

Karen A. Tourian, Claire Leurent, Jay Graepel, et al

Article

A 10-Month, Open-Label Evaluation of Desvenlafaxine in Outpatients With Major Depressive Disorder

April 7, 2011

The authors of this study evaluated the long-term safety of desvenlafaxine during open-label treatment in adult outpatients with a primary diagnosis of major depressive disorder.

Karen A. Tourian, Bruno Pitrosky, S. Krishna Padmanabhan, et al

Article

Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder: A Systematic Review of Clinical Trials

June 24, 2010

Read this article to review data on the clinical pharmacology, efficacy, safety, and tolerability of desvenlafaxine and to discover clinical practice considerations and future directions in desvenlafaxine research.

Michael R. Liebowitz, Karen A. Tourian

Article

Desvenlafaxine and Weight Change in Major Depressive Disorder

February 25, 2010

This analysis of data from 10 studies examined weight change during short- and longer-term treatment with desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor.Â

Karen A. Tourian, Claire Leurent, Jay Graepel, et al